Record-Breaking Meeting of IVD and Lab Industry Tackles Key Healthcare Issues

Record-Breaking Meeting of IVD and Lab Industry Tackles Key Healthcare Issues

If there's a problem, find a pathologist. And a lab technician and an IVD company for the equipment. That was the implied message of the world's largest meeting of lab professionals as they tackled the largest challenges in healthcare - opioid addiction, healthcare associated infections (HAIs), near-patient results, autism, Alzheimer's, faster test results, better IT. These were all issues discussed at scientific panels and in vendor booths at the meeting. Kalorama Information was on site and noted the developments at the meeting.


VIDEO: What We'll Be Watching Out for at the #AACC2017 Clinical Expo

VIDEO: What We'll Be Watching Out for at the #AACC2017 Clinical Expo

Test migration, new assays, molecular POC and other trends will be what we are tracking at this year's #AACC2017


Earnings Season for IVD: What Does it Say About 2017

Earnings Season for IVD: What Does it Say About 2017

Earnings season is here. Many diagnostic companies are reporting their results for 2016, and some are providing guidance on what they expect for 2017. As might be expected, results for the year 2016 vary greatly among different companies. Kalorama's IVD analysts look into the 2016 revenue report to get a sense of what this means for the coming year.


Top 5 News Stories in IVD - February 2017

Top 5 News Stories in IVD - February 2017

Roche moves into the hematology market with a European product launch, new options come to market for prenatal and newborn screening, and the FDA approves the first commercial Zika test for whole blood samples. Also, scientists design a 1-cent lab-on-a-chip and evidence builds for the power of breath tests to detect a variety of diseases. These are among the top news stories in IVD.


Autoimmune Diagnostics: Analyst Q&A

Autoimmune Diagnostics: Analyst Q&A

What are the main trends in autoimmune testing? What growth rate is expected for revenues, and what are the main companies competing in this important in vitro diagnostic segment. What are the key future trends in AIIVD? We asked these questions of the analyst of Kalorama Information's most recent market research study: Automimmune IVD Testing Markets


Uncertain Consequences for U.S. Health Care Post-Election

Uncertain Consequences for U.S. Health Care Post-Election

Incoming Republican congressional majorities and an administration of president-elect Trump have injected plenty of uncertainty into the U.S. healthcare system. Dismantling the Affordable Care Act (ACA) will be a legislative priority of the new regime, but could take years to accomplish. Which ACA provisions are kept and how coverage is preserved for newly insured individuals are currently open questions.


Join Kalorama Information on September 22 for Our Live Webinar “State of the IVD Market in 2016”

Join Kalorama Information on September 22 for Our Live Webinar “State of the IVD Market in 2016”

Kalorama Information publisher Bruce Carlson and IVD market analyst Emil Salazar will host the webinar at 2pm EST on September 22. Interested listeners should register for the event using the link provided in this post.


With Final Rule, PAMA Set to Spark Changes in Lab Market and IVD Strategy

With Final Rule, PAMA Set to Spark Changes in Lab Market and IVD Strategy

This blog post reviews regulatory developments in the United States relevant to the clinical lab services and U.S. in vitro diagnostics (IVD) markets. For more information regarding recent market developments or trends in either market, Kalorama Information offers the market research reports United States Market for In Vitro Diagnostic Tests and Clinical Laboratory Services Market.

In late June of this year, the Centers for Medicare and Medicaid Services (CMS) announced the final rule of the 2...

  • by bcarlson@marketresearch.com
  • May 28 2014
  • U.S. IVD


For Roche, Brave Face on Reimbursement Cuts

For Roche, Brave Face on Reimbursement Cuts

Roche won’t cut prices despite reimbursement reductions, according to a recent Reuters story. This isn’t surprising according to Kalorama. We think that there’s a ’have to buy’ element to the diagnostics industry that will sustain markets. We cover the United States in vitro diagnostic industry in our new report.

"Labs will still have to keep buying and some companies will just ride out the storm," said Kalorama’s Emil Salazar, author of our US IVD report. "At most the US is 25% of Roche’s dia...

  • by esalazar@marketresearch.com
  • April 7 2014
  • U.S. IVD


Targeting Growth in the U.S. IVD Market: Projected Test Segment Metrics through 2018

Targeting Growth in the U.S. IVD Market: Projected Test Segment Metrics through 2018

An IVD company looking to expand or establish its presence in the U.S. market is advised to pick its spots; many IVD segments are highly competitive or feature clear-cut market leaders. Yet in other segments, unmet clinical demand and responsive innovation will create billions of dollars in added market revenue over the next five years. Derived from market segmentation and projections in The U.S. Market for In Vitro Diagnostic Tests , Kalorama Information introduces the following relative market...